150:@0.085199:0.957873:0.109688:0.957873:0.109688:0.938882:0.085199:0.938882:0.007305:0.008593:0.008591
6:@0.038824:0.497523:0.060302:0.497523:0.060302:0.450045:0.038824:0.450045:0.021478
CHAPTER 6:@0.117647:0.067219:0.190817:0.067219:0.190817:0.047140:0.117647:0.047140:0.009172:0.009650:0.008799:0.008861:0.007388:0.007906:0.009359:0.003320:0.008716
Introduction:@0.117647:0.126494:0.256049:0.126494:0.256049:0.098384:0.117647:0.098384:0.006217:0.013626:0.010343:0.012928:0.013132:0.013103:0.013015:0.012722:0.010343:0.006217:0.013132:0.013626
Leukemias are the most common form of pediatric cancers and account for approxi-:@0.117647:0.168344:0.852941:0.168344:0.852941:0.147971:0.117647:0.147971:0.011824:0.009131:0.011550:0.010272:0.009039:0.017645:0.005796:0.009291:0.007670:0.006346:0.009085:0.007442:0.009039:0.006346:0.006620:0.011299:0.009039:0.006346:0.017488:0.010955:0.007512:0.006437:0.006346:0.008994:0.010843:0.017645:0.017485:0.010843:0.011756:0.006346:0.006026:0.010843:0.007807:0.017645:0.006346:0.010843:0.006209:0.006346:0.011505:0.009108:0.011391:0.005796:0.008811:0.006437:0.007807:0.005547:0.008994:0.006346:0.009108:0.009085:0.011596:0.008994:0.009039:0.007624:0.007670:0.006346:0.009087:0.011596:0.011391:0.006346:0.009291:0.008994:0.008994:0.010820:0.011413:0.011391:0.006437:0.006346:0.006026:0.010843:0.007807:0.006346:0.008811:0.011048:0.011071:0.007442:0.010820:0.010089:0.005659:0.007533
mately 30% of childhood cancer incidences . Leukemias develop from hematopoietic :@0.117647:0.188923:0.857013:0.188923:0.857013:0.168550:0.117647:0.168550:0.017577:0.008811:0.006209:0.008948:0.005182:0.009724:0.005250:0.010432:0.010432:0.015043:0.005250:0.010843:0.006209:0.005250:0.008765:0.011459:0.005752:0.005182:0.011528:0.011299:0.011276:0.011276:0.011391:0.005250:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.005250:0.005615:0.011596:0.008994:0.005547:0.011322:0.009039:0.011596:0.008994:0.009039:0.007670:0.018291:0.004497:0.005250:0.011824:0.009131:0.011550:0.010272:0.009039:0.017645:0.005798:0.009291:0.007670:0.005250:0.011322:0.009336:0.009633:0.008948:0.005182:0.010820:0.011276:0.005250:0.006414:0.007442:0.010843:0.017645:0.005250:0.011299:0.009039:0.017577:0.008811:0.006209:0.010820:0.011505:0.010843:0.005547:0.009131:0.006437:0.005547:0.008994:0.004109
375:@0.486323:0.181307:0.504568:0.181307:0.504568:0.169429:0.486323:0.169429:0.006082:0.006082:0.006082
progenitors in the bone marrow or the thymus and cause an abnormal increase of white :@0.117647:0.209502:0.856984:0.209502:0.856984:0.189129:0.117647:0.189129:0.011071:0.007442:0.011048:0.009656:0.009039:0.011756:0.005273:0.006209:0.010843:0.007624:0.007670:0.004223:0.005615:0.011756:0.004223:0.006620:0.011299:0.009039:0.004223:0.011254:0.010843:0.011596:0.009039:0.004223:0.017577:0.009085:0.007807:0.007442:0.010866:0.014723:0.004223:0.010843:0.007807:0.004223:0.006620:0.011299:0.009039:0.004223:0.006620:0.011071:0.009724:0.017280:0.011413:0.007670:0.004223:0.009087:0.011596:0.011391:0.004223:0.009108:0.008811:0.011413:0.007873:0.009039:0.004223:0.009087:0.011756:0.004223:0.009108:0.010820:0.011596:0.010843:0.007807:0.017577:0.009405:0.005250:0.004223:0.005615:0.011596:0.008994:0.007442:0.009291:0.009291:0.007873:0.009039:0.004223:0.010845:0.006209:0.004223:0.014789:0.011459:0.005273:0.006209:0.009039:0.004109
blood cells . Depending on the type of affected lineage (myeloid or lymphoid) and the :@0.117647:0.230080:0.857055:0.230080:0.857055:0.209707:0.117647:0.209707:0.010911:0.005182:0.011276:0.011276:0.011391:0.004543:0.008994:0.008948:0.005385:0.005250:0.007670:0.018245:0.004497:0.004543:0.016230:0.009131:0.011502:0.009039:0.011596:0.011391:0.005615:0.011459:0.009861:0.004543:0.010843:0.011756:0.004543:0.006620:0.011299:0.009039:0.004543:0.006437:0.009724:0.011505:0.009039:0.004543:0.010843:0.006209:0.004543:0.009085:0.005969:0.005787:0.009106:0.009108:0.006209:0.009108:0.011391:0.004543:0.005250:0.005615:0.011596:0.009291:0.009199:0.009656:0.009039:0.004543:0.006939:0.017255:0.009521:0.008948:0.005182:0.010843:0.005547:0.011391:0.004543:0.010845:0.007807:0.004543:0.005182:0.009724:0.017280:0.011162:0.011299:0.010845:0.005545:0.011391:0.006939:0.004543:0.009085:0.011596:0.011391:0.004543:0.006620:0.011299:0.009039:0.004109
376:@0.208473:0.222464:0.226719:0.222464:0.226719:0.210587:0.208473:0.210587:0.006082:0.006082:0.006082
kinetics of the disease (acute or chronic), leukemias can be subdivided into acute my-:@0.117647:0.250659:0.852941:0.250659:0.852941:0.230286:0.117647:0.230286:0.010706:0.005615:0.011596:0.009131:0.006437:0.005547:0.008994:0.007670:0.005775:0.010843:0.006209:0.005775:0.006620:0.011302:0.009039:0.005775:0.011391:0.005615:0.007875:0.009291:0.009291:0.007875:0.009039:0.005775:0.006939:0.009291:0.009106:0.011071:0.006209:0.009039:0.005775:0.010843:0.007807:0.005775:0.008765:0.011459:0.007442:0.010843:0.011756:0.005547:0.008994:0.006939:0.004497:0.005775:0.005182:0.009131:0.011550:0.010272:0.009039:0.017645:0.005798:0.009291:0.007670:0.005775:0.009108:0.009085:0.011756:0.005775:0.011251:0.009039:0.005775:0.007510:0.011345:0.011254:0.011391:0.005547:0.009838:0.005547:0.011322:0.009108:0.011391:0.005775:0.005615:0.011391:0.006209:0.011048:0.005775:0.009291:0.009108:0.011071:0.006209:0.009039:0.005775:0.017257:0.009747:0.007533
eloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia :@0.117647:0.271238:0.857070:0.271238:0.857070:0.250865:0.117647:0.250865:0.008948:0.005182:0.010843:0.005547:0.011391:0.004520:0.005182:0.009131:0.011550:0.010272:0.009039:0.017645:0.005798:0.009291:0.004520:0.006939:0.014929:0.019608:0.011619:0.006939:0.004497:0.004520:0.009291:0.009108:0.011071:0.006209:0.009039:0.004520:0.005182:0.009724:0.017280:0.011162:0.011299:0.010957:0.010911:0.005433:0.009291:0.007510:0.006437:0.005547:0.008994:0.004520:0.005182:0.009131:0.011550:0.010272:0.009039:0.017645:0.005796:0.009291:0.004520:0.006939:0.014929:0.011619:0.011619:0.006939:0.004497:0.004520:0.008765:0.011459:0.007442:0.010843:0.011756:0.005547:0.008994:0.004520:0.017257:0.009519:0.008948:0.005182:0.010843:0.005547:0.011391:0.004520:0.005182:0.009128:0.011550:0.010274:0.009039:0.017645:0.005796:0.009291:0.004109
(CML) and chronic lymphocytic leukemia (CLL). These subtypes can be further subdi-:@0.117647:0.291816:0.852941:0.291816:0.852941:0.271444:0.117647:0.271444:0.006939:0.014678:0.019608:0.011619:0.006939:0.004565:0.009085:0.011598:0.011391:0.004565:0.008765:0.011459:0.007442:0.010845:0.011756:0.005547:0.008994:0.004565:0.005182:0.009724:0.017280:0.011165:0.011299:0.011274:0.009382:0.009724:0.006437:0.005547:0.008994:0.004565:0.005182:0.009131:0.011550:0.010272:0.009039:0.017645:0.005798:0.009291:0.004565:0.006939:0.014678:0.011619:0.011619:0.006939:0.004497:0.004565:0.011470:0.011311:0.009039:0.007875:0.009039:0.004565:0.007510:0.011345:0.010797:0.006437:0.009724:0.011505:0.009039:0.007670:0.004565:0.009108:0.009085:0.011756:0.004565:0.011251:0.009039:0.004565:0.006369:0.011413:0.007967:0.006620:0.011299:0.009039:0.007807:0.004565:0.007510:0.011345:0.011254:0.011391:0.005656:0.007533
vided based on molecular abnormalities or immunophenotypic presentation and pres-:@0.117647:0.312395:0.852941:0.312395:0.852941:0.292022:0.117647:0.292022:0.009838:0.005547:0.011322:0.009108:0.011391:0.005033:0.011117:0.009291:0.007875:0.009108:0.011391:0.005033:0.010845:0.011756:0.005033:0.017485:0.010934:0.005182:0.009108:0.009108:0.011550:0.005433:0.009085:0.007807:0.005033:0.009110:0.010818:0.011598:0.010843:0.007807:0.017577:0.009402:0.005250:0.005273:0.006437:0.005547:0.009039:0.007670:0.005045:0.010843:0.007807:0.005033:0.005615:0.017645:0.017280:0.011413:0.011596:0.010820:0.011162:0.011299:0.009039:0.011598:0.010820:0.006437:0.009724:0.011069:0.005547:0.008994:0.005045:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006551:0.008811:0.006437:0.005547:0.010843:0.011756:0.005033:0.009085:0.011598:0.011391:0.005033:0.011071:0.007442:0.009039:0.007652:0.007533
ent with differing prognostic predictions:@0.117647:0.332974:0.455798:0.332974:0.455798:0.312601:0.117647:0.312601:0.009039:0.011391:0.006437:0.003607:0.014723:0.005273:0.006620:0.011459:0.003607:0.011391:0.005615:0.005969:0.005784:0.009039:0.007807:0.005615:0.011459:0.009861:0.003607:0.011071:0.007442:0.011048:0.009861:0.011596:0.010957:0.007512:0.006437:0.005545:0.008994:0.003607:0.011071:0.007442:0.009108:0.011391:0.005547:0.009106:0.006437:0.005547:0.010843:0.011619:0.007670
377 378:@0.455840:0.325358:0.494952:0.325358:0.494952:0.313480:0.455840:0.313480:0.006082:0.006082:0.006082:0.002621:0.006082:0.006082:0.006082
,:@0.474085:0.325358:0.476707:0.325358:0.476707:0.313480:0.474085:0.313480:0.002622
. While the overall survival rate of pediatric :@0.494951:0.332974:0.857052:0.332974:0.857052:0.312601:0.494951:0.312601:0.004497:0.003616:0.020704:0.011459:0.005752:0.005182:0.009039:0.003616:0.006620:0.011299:0.009039:0.003618:0.010866:0.009633:0.009039:0.007898:0.009405:0.005385:0.005250:0.003618:0.007510:0.011413:0.008400:0.009838:0.005547:0.009838:0.009405:0.005250:0.003618:0.007898:0.008811:0.006209:0.009039:0.003616:0.010843:0.006209:0.003616:0.011505:0.009108:0.011391:0.005798:0.008811:0.006437:0.007807:0.005547:0.008994:0.004109
leukemias has drastically increased over the past decades, with 90% for ALL and 75% :@0.117647:0.353553:0.857164:0.353553:0.857164:0.333180:0.117647:0.333180:0.005182:0.009131:0.011550:0.010272:0.009039:0.017645:0.005798:0.009291:0.007670:0.006072:0.011391:0.009291:0.007670:0.006072:0.011391:0.007898:0.009291:0.007510:0.006437:0.005547:0.009108:0.009405:0.005387:0.005182:0.009724:0.006072:0.005615:0.011596:0.008994:0.007442:0.009291:0.009291:0.007875:0.009108:0.011391:0.006072:0.010866:0.009633:0.009039:0.007807:0.006072:0.006620:0.011299:0.009039:0.006072:0.011365:0.009291:0.007512:0.006437:0.006072:0.011322:0.009108:0.009108:0.009291:0.011322:0.009039:0.007670:0.004497:0.006072:0.014723:0.005271:0.006620:0.011459:0.006072:0.010432:0.010432:0.015043:0.006072:0.006024:0.010845:0.007807:0.006072:0.014929:0.011619:0.011619:0.006072:0.009085:0.011596:0.011391:0.006072:0.010432:0.010432:0.015043:0.004109
for AML, refractory or relapsed patients still face poor prognosis, therefore requiring :@0.117647:0.374131:0.857027:0.374131:0.857027:0.353758:0.117647:0.353758:0.006026:0.010843:0.007807:0.006506:0.014929:0.019608:0.011619:0.004497:0.006506:0.007442:0.009039:0.006414:0.007898:0.009291:0.009106:0.006209:0.010843:0.008400:0.009724:0.006506:0.010843:0.007807:0.006506:0.007442:0.008948:0.005433:0.008811:0.011185:0.007875:0.009108:0.011391:0.006506:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.006506:0.007510:0.006437:0.005752:0.005387:0.005250:0.006506:0.006209:0.009291:0.008994:0.009039:0.006506:0.011505:0.011274:0.010843:0.007807:0.006506:0.011071:0.007442:0.011048:0.009861:0.011596:0.010957:0.007601:0.005615:0.007670:0.004497:0.006506:0.006620:0.011302:0.009039:0.007442:0.009039:0.006024:0.010845:0.007442:0.009039:0.006506:0.007442:0.009108:0.010706:0.011413:0.005615:0.007807:0.005615:0.011459:0.009861:0.004109
accurate diagnosis at initial presentation as well as at recurrence:@0.117647:0.394710:0.663682:0.394710:0.663682:0.374337:0.117647:0.374337:0.009291:0.008994:0.009108:0.011413:0.007898:0.008811:0.006209:0.009039:0.005638:0.011391:0.005798:0.009199:0.009861:0.011596:0.010957:0.007601:0.005615:0.007670:0.005638:0.008811:0.006437:0.005638:0.005615:0.011756:0.005271:0.006437:0.005798:0.009405:0.005250:0.005638:0.011071:0.007442:0.009039:0.007873:0.009039:0.011391:0.006551:0.008811:0.006437:0.005547:0.010843:0.011756:0.005638:0.009291:0.007670:0.005638:0.014518:0.008948:0.005387:0.005250:0.005638:0.009291:0.007670:0.005638:0.008811:0.006437:0.005638:0.007442:0.009108:0.009108:0.011413:0.007807:0.007442:0.009039:0.011596:0.008994:0.009039
377 379:@0.663615:0.387094:0.702726:0.387094:0.702726:0.375216:0.663615:0.375216:0.006082:0.006082:0.006082:0.002621:0.006082:0.006082:0.006082
,:@0.681860:0.387094:0.684481:0.387094:0.684481:0.375216:0.681860:0.375216:0.002622
. Key to the man-:@0.702726:0.394710:0.852941:0.394710:0.852941:0.374337:0.702726:0.374337:0.004497:0.005638:0.013970:0.009336:0.009724:0.005638:0.006209:0.011048:0.005638:0.006620:0.011299:0.009039:0.005638:0.017577:0.009087:0.011723:0.007533
agement of leukemias is monitoring of minimal residual disease (MRD) – small traces :@0.117647:0.415289:0.857050:0.415289:0.857050:0.394916:0.117647:0.394916:0.009199:0.009656:0.009039:0.017485:0.009039:0.011391:0.006437:0.005284:0.010843:0.006209:0.005284:0.005182:0.009131:0.011550:0.010272:0.009039:0.017645:0.005798:0.009291:0.007670:0.005284:0.005615:0.007670:0.005284:0.017485:0.010843:0.011756:0.005273:0.006209:0.010843:0.007807:0.005615:0.011459:0.009861:0.005284:0.010843:0.006209:0.005284:0.017645:0.005615:0.011756:0.005615:0.017577:0.009405:0.005250:0.005284:0.007442:0.009039:0.007601:0.005547:0.011048:0.011596:0.009405:0.005250:0.005284:0.011391:0.005615:0.007873:0.009291:0.009291:0.007875:0.009039:0.005284:0.006939:0.019608:0.013376:0.016139:0.006939:0.005284:0.011801:0.005284:0.007601:0.017577:0.009405:0.005387:0.005250:0.005284:0.006437:0.007898:0.009291:0.008994:0.009039:0.007670:0.004109
of leukemic cells that can still be detected by sensitive methods like flow cytometry or :@0.117647:0.435867:0.857052:0.435867:0.857052:0.415494:0.117647:0.415494:0.010843:0.006209:0.005615:0.005182:0.009131:0.011550:0.010272:0.009039:0.017645:0.005547:0.008994:0.005615:0.008994:0.008948:0.005387:0.005250:0.007670:0.005615:0.006620:0.011391:0.008811:0.006437:0.005615:0.009108:0.009085:0.011756:0.005615:0.007510:0.006437:0.005752:0.005387:0.005250:0.005615:0.011254:0.009039:0.005615:0.011322:0.009131:0.006209:0.009108:0.009108:0.006209:0.009108:0.011391:0.005615:0.010843:0.009724:0.005615:0.007875:0.009039:0.011619:0.007601:0.005273:0.006437:0.005547:0.009633:0.009039:0.005615:0.017485:0.009131:0.006620:0.011299:0.011276:0.011391:0.007670:0.005615:0.005250:0.005752:0.010272:0.009039:0.005615:0.005638:0.005570:0.010866:0.014723:0.005615:0.009382:0.009724:0.006209:0.010843:0.017485:0.009131:0.006437:0.008400:0.009724:0.005615:0.010843:0.007807:0.004109
PCR . MRD is a strong prognostic factor widely used for risk group stratification and :@0.117647:0.456446:0.857126:0.456446:0.857126:0.436073:0.117647:0.436073:0.012167:0.014678:0.013376:0.018244:0.004497:0.005136:0.019608:0.013376:0.016139:0.005136:0.005615:0.007670:0.005136:0.009291:0.005136:0.007510:0.006437:0.007442:0.010843:0.011459:0.009861:0.005136:0.011073:0.007442:0.011048:0.009861:0.011596:0.010957:0.007510:0.006437:0.005547:0.008994:0.005136:0.006209:0.009291:0.009108:0.006209:0.010843:0.007807:0.005136:0.014723:0.005547:0.011322:0.008948:0.005182:0.009724:0.005136:0.011413:0.007875:0.009106:0.011391:0.005136:0.006026:0.010843:0.007807:0.005136:0.007807:0.005615:0.007553:0.010523:0.005136:0.009861:0.007442:0.010820:0.011071:0.011276:0.005136:0.007510:0.006437:0.007898:0.008811:0.006437:0.005615:0.005684:0.005615:0.009108:0.008811:0.006437:0.005547:0.010843:0.011756:0.005136:0.009087:0.011596:0.011391:0.004109
380:@0.157867:0.448830:0.176113:0.448830:0.176113:0.436953:0.157867:0.436953:0.006082:0.006082:0.006082
other clinical decision-making:@0.117647:0.477025:0.373487:0.477025:0.373487:0.456652:0.117647:0.456652:0.010820:0.006620:0.011299:0.009039:0.007807:0.003310:0.008765:0.005250:0.005615:0.011756:0.005547:0.009106:0.009405:0.005250:0.003310:0.011322:0.009108:0.008994:0.005615:0.007601:0.005547:0.010843:0.011756:0.007533:0.017577:0.009405:0.010706:0.005615:0.011459:0.009861
381,382:@0.373491:0.469409:0.412603:0.469409:0.412603:0.457531:0.373491:0.457531:0.006082:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082
. Molecular MRD monitoring relies on genetic mark-:@0.412601:0.477025:0.852941:0.477025:0.852941:0.456652:0.412601:0.456652:0.004497:0.003310:0.018969:0.010934:0.005182:0.009108:0.009106:0.011550:0.005433:0.009085:0.007807:0.003310:0.019608:0.013376:0.016139:0.003310:0.017485:0.010843:0.011756:0.005273:0.006209:0.010843:0.007807:0.005615:0.011459:0.009861:0.003310:0.007442:0.008948:0.005250:0.005547:0.009039:0.007670:0.003310:0.010843:0.011756:0.003310:0.009656:0.009039:0.011596:0.009131:0.006437:0.005547:0.008994:0.003310:0.017577:0.009085:0.007601:0.010536:0.007533
ers that specifically identify the leukemic cells  Genetic abnormalities such as the unique :@0.117647:0.497603:0.857047:0.497603:0.857047:0.477231:0.117647:0.477231:0.009039:0.007624:0.007670:0.004040:0.006620:0.011391:0.008811:0.006437:0.004040:0.007510:0.011505:0.009108:0.008994:0.005615:0.005684:0.005615:0.009108:0.009405:0.005385:0.005184:0.009724:0.004040:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.006503:0.009724:0.004040:0.006620:0.011299:0.009039:0.004040:0.005182:0.009131:0.011550:0.010272:0.009039:0.017645:0.005547:0.008994:0.004040:0.008994:0.008948:0.005387:0.005250:0.007670:0.004496:0.004040:0.015819:0.009039:0.011596:0.009131:0.006437:0.005547:0.008994:0.004040:0.009108:0.010820:0.011596:0.010843:0.007807:0.017577:0.009405:0.005250:0.005273:0.006437:0.005547:0.009039:0.007670:0.004040:0.007510:0.011345:0.008765:0.011459:0.004040:0.009291:0.007670:0.004040:0.006620:0.011299:0.009039:0.004040:0.011413:0.011756:0.005547:0.010703:0.011345:0.009039:0.004109
.:@0.498464:0.497603:0.502960:0.497603:0.502960:0.477231:0.498464:0.477231:0.004497
breakpoint junctions created by genomic rearrangements are optimal biomarkers that :@0.117647:0.518182:0.857050:0.518182:0.857050:0.497809:0.117647:0.497809:0.010820:0.007442:0.009291:0.009405:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.006013:0.004953:0.011413:0.011596:0.009108:0.006437:0.005547:0.010843:0.011619:0.007670:0.006013:0.008994:0.007442:0.009291:0.008811:0.006209:0.009108:0.011391:0.006013:0.010843:0.009724:0.006015:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.006013:0.007442:0.009291:0.009085:0.007807:0.007898:0.009085:0.011459:0.009656:0.009039:0.017485:0.009039:0.011391:0.006437:0.007670:0.006015:0.009085:0.007442:0.009039:0.006013:0.010820:0.011048:0.006437:0.005615:0.017577:0.009405:0.005250:0.006013:0.010820:0.005547:0.010843:0.017577:0.009085:0.007601:0.010274:0.009039:0.007622:0.007670:0.006015:0.006620:0.011391:0.008811:0.006437:0.004109
reflect the disease burden:@0.117647:0.538761:0.331418:0.538761:0.331418:0.518388:0.117647:0.518388:0.007442:0.009039:0.005638:0.005570:0.009108:0.009108:0.006437:0.004109:0.006620:0.011299:0.009039:0.004109:0.011391:0.005615:0.007873:0.009291:0.009291:0.007875:0.009039:0.004109:0.010797:0.011413:0.007442:0.011322:0.009039:0.011756
69,166:@0.331417:0.531145:0.364447:0.531145:0.364447:0.519267:0.331417:0.519267:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082
.:@0.364446:0.538761:0.368943:0.538761:0.368943:0.518388:0.364446:0.518388:0.004497
A large proportion of leukemic subtypes are characterized by recurrent genomic rear-:@0.117647:0.579918:0.852941:0.579918:0.852941:0.559545:0.117647:0.559545:0.014929:0.005821:0.005433:0.009085:0.007624:0.009656:0.009039:0.005821:0.011071:0.007444:0.010820:0.011502:0.010843:0.007967:0.006437:0.005547:0.010843:0.011756:0.005821:0.010843:0.006209:0.005821:0.005182:0.009131:0.011550:0.010272:0.009039:0.017645:0.005547:0.008994:0.005821:0.007510:0.011345:0.010797:0.006437:0.009724:0.011502:0.009039:0.007670:0.005821:0.009085:0.007442:0.009039:0.005821:0.008765:0.011391:0.009085:0.007898:0.009291:0.009108:0.006209:0.009039:0.007807:0.005615:0.008834:0.009106:0.011391:0.005821:0.010843:0.009724:0.005821:0.007442:0.009108:0.009108:0.011413:0.007807:0.007442:0.009039:0.011391:0.006437:0.005821:0.009658:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.005821:0.007442:0.009291:0.009085:0.007304:0.007533
rangements which may lead to the formation of fusion genes:@0.117647:0.600497:0.621343:0.600497:0.621343:0.580124:0.117647:0.580124:0.007898:0.009085:0.011459:0.009656:0.009039:0.017485:0.009039:0.011391:0.006437:0.007670:0.003744:0.014792:0.011459:0.005547:0.008765:0.011459:0.003744:0.017577:0.008928:0.009724:0.003744:0.005182:0.009288:0.009291:0.011391:0.003744:0.006209:0.011048:0.003744:0.006620:0.011299:0.009039:0.003744:0.006026:0.010843:0.007807:0.017577:0.008811:0.006437:0.005547:0.010843:0.011756:0.003744:0.010843:0.006209:0.003744:0.006369:0.011413:0.007601:0.005547:0.010843:0.011756:0.003744:0.009656:0.009039:0.011596:0.009039:0.007670
383 31:@0.621324:0.592881:0.654354:0.592881:0.654354:0.581004:0.621324:0.581004:0.006082:0.006082:0.006082:0.002621:0.006082:0.006082
,:@0.639569:0.592881:0.642191:0.592881:0.642191:0.581004:0.639569:0.581004:0.002622
. Fusion gene formation :@0.654353:0.600497:0.857055:0.600497:0.857055:0.580124:0.654353:0.580124:0.004497:0.003744:0.010729:0.011413:0.007601:0.005547:0.010843:0.011756:0.003744:0.009656:0.009039:0.011596:0.009039:0.003744:0.006026:0.010843:0.007807:0.017577:0.008811:0.006437:0.005547:0.010843:0.011756:0.004109
is a complex mechanism and the originating fusion gene configurations are extreme-:@0.117647:0.621076:0.852941:0.621076:0.852941:0.600703:0.117647:0.600703:0.005615:0.007670:0.006483:0.009291:0.006483:0.008994:0.010843:0.017280:0.011162:0.005182:0.009108:0.010089:0.006483:0.017485:0.009108:0.008765:0.011391:0.009085:0.011756:0.005615:0.007601:0.017645:0.006483:0.009085:0.011596:0.011391:0.006483:0.006620:0.011299:0.009039:0.006483:0.010843:0.007807:0.005615:0.009861:0.005615:0.011685:0.008811:0.006437:0.005615:0.011459:0.009861:0.006483:0.006369:0.011413:0.007601:0.005547:0.010843:0.011756:0.006483:0.009656:0.009039:0.011596:0.009039:0.006483:0.008994:0.010843:0.011756:0.005684:0.005684:0.009861:0.011413:0.007898:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.006483:0.009085:0.007442:0.009039:0.006483:0.009108:0.010089:0.006437:0.007442:0.009039:0.017485:0.009039:0.007533
ly versatile. Whereas some events involve highly recurrent fusion gene configurations, :@0.117647:0.641654:0.856959:0.641654:0.856959:0.621281:0.117647:0.621281:0.005182:0.009724:0.005866:0.009633:0.009039:0.007624:0.007944:0.008811:0.006437:0.005752:0.005182:0.008743:0.004497:0.005866:0.020704:0.011299:0.009039:0.007442:0.009291:0.009291:0.007670:0.005866:0.007875:0.010843:0.017485:0.009039:0.005866:0.009336:0.009633:0.009039:0.011391:0.006437:0.007670:0.005866:0.005615:0.011368:0.009633:0.010934:0.005182:0.009633:0.009039:0.005866:0.011459:0.005615:0.009930:0.011573:0.005182:0.009724:0.005866:0.007442:0.009108:0.009108:0.011413:0.007807:0.007442:0.009039:0.011391:0.006437:0.005866:0.006366:0.011413:0.007601:0.005547:0.010843:0.011756:0.005866:0.009656:0.009039:0.011596:0.009039:0.005866:0.008994:0.010843:0.011756:0.005684:0.005684:0.009861:0.011413:0.007898:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004497:0.004109
such as the common :@0.117647:0.662233:0.296974:0.662233:0.296974:0.641860:0.117647:0.641860:0.007510:0.011345:0.008765:0.011459:0.004885:0.009291:0.007670:0.004885:0.006620:0.011299:0.009039:0.004885:0.008994:0.010843:0.017645:0.017485:0.010843:0.011756:0.004109
BCR-ABL1 :@0.297740:0.662702:0.402972:0.662702:0.402972:0.640680:0.297740:0.640680:0.013399:0.014495:0.013080:0.007624:0.015157:0.013217:0.012144:0.010888:0.005227
fusion or the rare :@0.403955:0.662233:0.555322:0.662233:0.555322:0.641860:0.403955:0.641860:0.006369:0.011413:0.007601:0.005547:0.010843:0.011756:0.004885:0.010843:0.007807:0.004885:0.006620:0.011299:0.009039:0.004885:0.007898:0.009087:0.007442:0.009039:0.004109
SIL-TAL1:@0.556084:0.662702:0.644401:0.662702:0.644401:0.640680:0.556084:0.640680:0.010500:0.007647:0.012030:0.007624:0.012326:0.015157:0.012144:0.010888
 deletion rearrangement, :@0.644401:0.662233:0.857055:0.662233:0.857055:0.641860:0.644401:0.641860:0.004885:0.011322:0.008948:0.005182:0.009131:0.006437:0.005547:0.010843:0.011756:0.004885:0.007442:0.009291:0.009085:0.007807:0.007898:0.009085:0.011459:0.009656:0.009039:0.017485:0.009039:0.011391:0.006437:0.004497:0.004109
others mainly involve a sole recurrent fusion partner gene:@0.117647:0.682812:0.611756:0.682812:0.611756:0.662439:0.117647:0.662439:0.010820:0.006620:0.011299:0.009039:0.007624:0.007670:0.005364:0.017577:0.009085:0.005615:0.011870:0.005182:0.009724:0.005364:0.005615:0.011368:0.009635:0.010934:0.005182:0.009633:0.009039:0.005364:0.009291:0.005364:0.007875:0.010934:0.005182:0.009039:0.005364:0.007442:0.009108:0.009108:0.011413:0.007807:0.007442:0.009039:0.011391:0.006437:0.005364:0.006366:0.011413:0.007601:0.005549:0.010840:0.011756:0.005364:0.011368:0.009085:0.007967:0.006437:0.011596:0.009039:0.007807:0.005364:0.009656:0.009039:0.011596:0.009039
384–386:@0.611805:0.675196:0.655176:0.675196:0.655176:0.663318:0.611805:0.663318:0.006082:0.006082:0.006082:0.006880:0.006082:0.006082:0.006082
. :@0.655174:0.682812:0.663780:0.682812:0.663780:0.662439:0.655174:0.662439:0.004497:0.004109
KMT2A :@0.665042:0.683281:0.744981:0.683281:0.744981:0.661259:0.665042:0.661259:0.014906:0.019996:0.013765:0.010888:0.015157:0.005227
for example:@0.746585:0.682812:0.847571:0.682812:0.847571:0.662439:0.746585:0.662439:0.006026:0.010843:0.007807:0.005364:0.009108:0.010089:0.009085:0.017280:0.011162:0.005182:0.009039
, :@0.847577:0.683281:0.858168:0.683281:0.858168:0.661259:0.847577:0.661259:0.005364:0.005227
is a promiscuous fusion partner gene and has been reported in >130 different fusion :@0.117647:0.703390:0.856934:0.703390:0.856934:0.683018:0.117647:0.683018:0.005615:0.007670:0.006506:0.009291:0.006506:0.011071:0.007442:0.010843:0.017645:0.005615:0.007875:0.009108:0.011345:0.010820:0.011413:0.007670:0.006506:0.006366:0.011413:0.007601:0.005547:0.010843:0.011756:0.006506:0.011368:0.009085:0.007967:0.006437:0.011596:0.009039:0.007807:0.006506:0.009656:0.009039:0.011596:0.009039:0.006506:0.009085:0.011596:0.011391:0.006506:0.011391:0.009291:0.007670:0.006506:0.011254:0.009108:0.009039:0.011756:0.006506:0.007442:0.009131:0.011505:0.010843:0.007967:0.006209:0.009108:0.011391:0.006506:0.005615:0.011756:0.006506:0.011550:0.010432:0.010432:0.010432:0.006506:0.011391:0.005615:0.005969:0.005784:0.009039:0.007442:0.009039:0.011393:0.006437:0.006506:0.006366:0.011413:0.007601:0.005547:0.010843:0.011756:0.004109
configurations:@0.117647:0.723969:0.240706:0.723969:0.240706:0.703596:0.117647:0.703596:0.008994:0.010843:0.011756:0.005684:0.005684:0.009861:0.011413:0.007898:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670
387,388:@0.240706:0.716353:0.279818:0.716353:0.279818:0.704476:0.240706:0.704476:0.006082:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082
. Additionally, the genomic position where the break occurs within :@0.279817:0.723969:0.857060:0.723969:0.857060:0.703596:0.279817:0.703596:0.004497:0.005730:0.014335:0.011322:0.011391:0.005271:0.006437:0.005547:0.010843:0.011690:0.009402:0.005387:0.005182:0.007992:0.004497:0.005730:0.006620:0.011299:0.009039:0.005730:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.005730:0.011505:0.010957:0.007601:0.005273:0.006437:0.005547:0.010843:0.011756:0.005730:0.014792:0.011299:0.009039:0.007442:0.009039:0.005730:0.006617:0.011302:0.009039:0.005730:0.010820:0.007442:0.009291:0.009405:0.010523:0.005730:0.011276:0.008994:0.009108:0.011413:0.007624:0.007670:0.005730:0.014723:0.005273:0.006620:0.011459:0.005615:0.011756:0.004109
the involved genes is very variable - even for highly recurrent fusion gene configurations. :@0.117647:0.744548:0.857075:0.744548:0.857075:0.724175:0.117647:0.724175:0.006620:0.011299:0.009039:0.003584:0.005615:0.011368:0.009633:0.010934:0.005182:0.009633:0.009108:0.011391:0.003584:0.009656:0.009039:0.011596:0.009039:0.007670:0.003584:0.005615:0.007670:0.003584:0.009633:0.009039:0.008400:0.009724:0.003584:0.009838:0.009085:0.007807:0.005798:0.009108:0.010911:0.005182:0.009039:0.003584:0.007533:0.003584:0.009336:0.009633:0.009039:0.011756:0.003584:0.006026:0.010843:0.007807:0.003584:0.011459:0.005615:0.009930:0.011573:0.005182:0.009724:0.003584:0.007442:0.009108:0.009108:0.011413:0.007807:0.007442:0.009039:0.011391:0.006437:0.003584:0.006369:0.011413:0.007601:0.005547:0.010843:0.011756:0.003584:0.009656:0.009039:0.011596:0.009039:0.003584:0.008994:0.010843:0.011756:0.005684:0.005684:0.009861:0.011413:0.007898:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004497:0.004109
However, this high level of versatility results in unique genomic breakpoint junctions, an :@0.117647:0.765127:0.857052:0.765127:0.857052:0.744754:0.117647:0.744754:0.016207:0.010866:0.014518:0.009336:0.009633:0.009039:0.006255:0.004497:0.003766:0.006620:0.011459:0.005615:0.007670:0.003766:0.011459:0.005615:0.009930:0.011459:0.003766:0.005182:0.009336:0.009633:0.008948:0.005250:0.003766:0.010843:0.006209:0.003766:0.009633:0.009039:0.007624:0.007944:0.008811:0.006437:0.005752:0.005250:0.005273:0.006437:0.009724:0.003766:0.007442:0.009039:0.007510:0.011550:0.004908:0.006437:0.007670:0.003766:0.005615:0.011756:0.003766:0.011413:0.011756:0.005547:0.010706:0.011345:0.009039:0.003766:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.003766:0.010820:0.007442:0.009291:0.009405:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.003766:0.004953:0.011413:0.011596:0.009108:0.006437:0.005547:0.010843:0.011619:0.007670:0.004497:0.003766:0.009085:0.011756:0.004109
acquired and patient-specific property of the tumor cells, and can therefore be exploited :@0.117647:0.785705:0.857150:0.785705:0.857150:0.765332:0.117647:0.765332:0.009291:0.008994:0.010706:0.011413:0.005615:0.007442:0.009108:0.011391:0.004143:0.009087:0.011596:0.011391:0.004154:0.011365:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533:0.007510:0.011505:0.009108:0.008994:0.005615:0.005684:0.005615:0.008994:0.004154:0.011071:0.007442:0.010820:0.011505:0.009039:0.007964:0.006437:0.009724:0.004154:0.010843:0.006209:0.004154:0.006620:0.011299:0.009039:0.004154:0.006163:0.011413:0.017485:0.010843:0.007807:0.004154:0.008994:0.008948:0.005387:0.005250:0.007670:0.004497:0.004154:0.009085:0.011596:0.011391:0.004154:0.009108:0.009085:0.011756:0.004154:0.006620:0.011299:0.009039:0.007442:0.009039:0.006026:0.010843:0.007442:0.009039:0.004154:0.011251:0.009039:0.004154:0.009108:0.010089:0.011162:0.005182:0.010843:0.005273:0.006209:0.009108:0.011391:0.004109
as a distinct, trackable biomarker.:@0.117647:0.806284:0.397321:0.806284:0.397321:0.785911:0.117647:0.785911:0.009291:0.007670:0.004109:0.009291:0.004109:0.011391:0.005615:0.007510:0.006437:0.005615:0.011596:0.009108:0.006437:0.004497:0.004109:0.006437:0.007896:0.009291:0.008765:0.010614:0.009108:0.010911:0.005182:0.009039:0.004109:0.010820:0.005547:0.010843:0.017577:0.009085:0.007601:0.010274:0.009039:0.006255:0.004497
Leukemias that arise from the lymphoid lineage mainly comprise a clonal outgrowth of :@0.117647:0.847441:0.857153:0.847441:0.857153:0.827068:0.117647:0.827068:0.011824:0.009131:0.011550:0.010272:0.009039:0.017645:0.005796:0.009291:0.007670:0.004565:0.006620:0.011391:0.008811:0.006437:0.004565:0.009085:0.007807:0.005615:0.007875:0.009039:0.004565:0.006414:0.007442:0.010843:0.017645:0.004554:0.006620:0.011299:0.009039:0.004565:0.005182:0.009724:0.017280:0.011162:0.011299:0.010843:0.005547:0.011391:0.004565:0.005250:0.005615:0.011596:0.009291:0.009199:0.009656:0.009039:0.004565:0.017577:0.009085:0.005615:0.011870:0.005182:0.009724:0.004565:0.008994:0.010843:0.017280:0.011071:0.007807:0.005615:0.007873:0.009039:0.004565:0.009291:0.004565:0.008765:0.005182:0.010843:0.011687:0.009405:0.005250:0.004565:0.010820:0.011071:0.006437:0.009861:0.007442:0.010866:0.014723:0.006620:0.011459:0.004565:0.010845:0.006209:0.004109
single transformed lymphoblasts . Lymphoblasts are immature lymphocytes that will :@0.117647:0.868020:0.857022:0.868020:0.857022:0.847647:0.117647:0.847647:0.007601:0.005615:0.011459:0.009930:0.005182:0.009039:0.005707:0.006437:0.007898:0.009085:0.011619:0.007601:0.006026:0.010843:0.007807:0.017485:0.009108:0.011391:0.005707:0.005182:0.009724:0.017280:0.011162:0.011299:0.010957:0.010911:0.005433:0.009291:0.007510:0.006437:0.007670:0.018254:0.004497:0.005707:0.010614:0.009724:0.017280:0.011162:0.011299:0.010957:0.010911:0.005433:0.009291:0.007510:0.006437:0.007670:0.005707:0.009085:0.007442:0.009039:0.005707:0.005615:0.017645:0.017577:0.008811:0.006163:0.011413:0.007442:0.009039:0.005707:0.005182:0.009724:0.017280:0.011162:0.011299:0.011276:0.009382:0.009724:0.006209:0.009039:0.007670:0.005707:0.006620:0.011391:0.008811:0.006437:0.005707:0.014723:0.005752:0.005387:0.005250:0.004109
389:@0.396052:0.860404:0.414297:0.860404:0.414297:0.848527:0.396052:0.848527:0.006082:0.006082:0.006082
become the effectors of the adaptive immune system, which recognizes millions or bil-:@0.117647:0.888599:0.852941:0.888599:0.852941:0.868226:0.117647:0.868226:0.011254:0.009108:0.008994:0.010843:0.017485:0.009039:0.005068:0.006620:0.011299:0.009039:0.005068:0.009039:0.005969:0.005787:0.009108:0.009108:0.006209:0.010843:0.007624:0.007670:0.005068:0.010843:0.006209:0.005068:0.006620:0.011299:0.009039:0.005068:0.009291:0.011573:0.008811:0.011048:0.006437:0.005547:0.009633:0.009039:0.005068:0.005615:0.017645:0.017278:0.011413:0.011596:0.009039:0.005068:0.007761:0.009724:0.007512:0.006209:0.009039:0.017645:0.004497:0.005068:0.014789:0.011459:0.005547:0.008765:0.011459:0.005068:0.007442:0.009108:0.008994:0.011048:0.009861:0.011756:0.005615:0.008834:0.009039:0.007670:0.005068:0.017645:0.005752:0.005387:0.005250:0.005547:0.010843:0.011619:0.007670:0.005068:0.010843:0.007807:0.005068:0.010820:0.005752:0.005227:0.007533
lions of different antigens thanks to a highly diverse repertoire of antigen recognition :@0.117647:0.909178:0.857073:0.909178:0.857073:0.888805:0.117647:0.888805:0.005250:0.005547:0.010843:0.011619:0.007670:0.006255:0.010843:0.006209:0.006255:0.011391:0.005615:0.005969:0.005784:0.009039:0.007442:0.009039:0.011391:0.006437:0.006255:0.009085:0.011391:0.006437:0.005615:0.009656:0.009039:0.011619:0.007670:0.006255:0.006620:0.011391:0.009085:0.011870:0.010523:0.007670:0.006255:0.006209:0.011048:0.006255:0.009291:0.006255:0.011459:0.005615:0.009927:0.011573:0.005182:0.009724:0.006255:0.011391:0.005547:0.009635:0.009039:0.007622:0.007875:0.009039:0.006255:0.007444:0.009128:0.011505:0.009039:0.007967:0.006209:0.010843:0.005615:0.007442:0.009039:0.006255:0.010845:0.006209:0.006255:0.009085:0.011391:0.006437:0.005615:0.009656:0.009039:0.011756:0.006255:0.007442:0.009108:0.008994:0.011048:0.009861:0.011756:0.005273:0.006437:0.005545:0.010845:0.011756:0.004109